| Schedule of Company's Consolidated Statements of Operations |
The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under U.S. GAAP to the Company’s total consolidated net loss in the Condensed Consolidated Statements of Operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended June 30, |
|
|
For the Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Product sales |
|
$ |
27,241 |
|
|
$ |
33,637 |
|
|
$ |
58,134 |
|
|
$ |
71,531 |
|
License and collaboration revenue |
|
|
6,500 |
|
|
|
— |
|
|
|
6,500 |
|
|
|
— |
|
Total revenue |
|
|
33,741 |
|
|
|
33,637 |
|
|
|
64,634 |
|
|
|
71,531 |
|
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
7,855 |
|
|
|
8,447 |
|
|
|
15,250 |
|
|
|
18,013 |
|
Commercial |
|
|
19,872 |
|
|
|
21,612 |
|
|
|
40,083 |
|
|
|
42,786 |
|
General and administrative |
|
|
10,546 |
|
|
|
7,364 |
|
|
|
22,191 |
|
|
|
14,825 |
|
Research and development |
|
|
7,529 |
|
|
|
8,865 |
|
|
|
15,364 |
|
|
|
17,921 |
|
Clinical & regulatory |
|
|
1,709 |
|
|
|
1,352 |
|
|
|
3,345 |
|
|
|
2,663 |
|
Total costs and expenses |
|
|
47,511 |
|
|
|
47,640 |
|
|
|
96,233 |
|
|
|
96,208 |
|
Loss from operations |
|
|
(13,770 |
) |
|
|
(14,003 |
) |
|
|
(31,599 |
) |
|
|
(24,677 |
) |
Other income (expense), net: |
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(3 |
) |
|
|
(5 |
) |
|
|
(6 |
) |
|
|
(11 |
) |
Interest and other income |
|
|
1,764 |
|
|
|
2,254 |
|
|
|
3,718 |
|
|
|
4,762 |
|
Loss before income taxes |
|
|
(12,009 |
) |
|
|
(11,754 |
) |
|
|
(27,887 |
) |
|
|
(19,926 |
) |
Income tax expense |
|
|
88 |
|
|
|
32 |
|
|
|
94 |
|
|
|
50 |
|
Net loss |
|
$ |
(12,097 |
) |
|
$ |
(11,786 |
) |
|
$ |
(27,981 |
) |
|
$ |
(19,976 |
) |
|